Efficacy and safety of omalizumab in nasal polyposis: two randomized phase III trials.

[1]  C. Bachert,et al.  Clinical Research Needs for the Management of Chronic Rhinosinusitis with Nasal Polyps in the New Era of Biologics. A National Institute of Allergy and Infectious Diseases Workshop. , 2020, The journal of allergy and clinical immunology. In practice.

[2]  D. Wang,et al.  European Position Paper on Rhinosinusitis and Nasal Polyps 2020. , 2020, Rhinology.

[3]  C. Bachert,et al.  The GALEN rhinosinusitis cohort: chronic rhinosinusitis with nasal polyps affects health-related quality of life. , 2019, Rhinology.

[4]  C. Bachert,et al.  Twelve-year follow-up study after endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyposis , 2019, Clinical and Translational Allergy.

[5]  Lihua Sun,et al.  A head-to-head comparison of EQ-5D-5 L and SF-6D in Chinese patients with low back pain , 2019, Health and Quality of Life Outcomes.

[6]  V. Ramakrishnan,et al.  The Role of Staphylococcus aureus in Patients with Chronic Sinusitis and Nasal Polyposis , 2019, Current Allergy and Asthma Reports.

[7]  W. Fokkens,et al.  Prevalence of chronic rhinosinusitis in the general population based on sinus radiology and symptomatology , 2019, The Journal of allergy and clinical immunology.

[8]  A. Peters,et al.  Clinical Characteristics of Patients with Chronic Rhinosinusitis without Nasal Polyps in an Academic Setting. , 2019, The journal of allergy and clinical immunology. In practice.

[9]  S. Hamada,et al.  Allergic conversion of protective mucosal immunity against nasal bacteria in patients with chronic rhinosinusitis with nasal polyposis , 2019, The Journal of allergy and clinical immunology.

[10]  C. Bachert,et al.  Elevated IgE M1 prime transcripts in nasal tissues in patients with nasal polyps and asthma. , 2019, The Journal of allergy and clinical immunology.

[11]  Andrew A. White,et al.  Diagnosis and management of NSAID‐Exacerbated Respiratory Disease (N‐ERD)—a EAACI position paper , 2018, Allergy.

[12]  S. Nguyen,et al.  Systematic Review and Meta-analysis of SNOT-22 Outcomes after Surgery for Chronic Rhinosinusitis with Nasal Polyposis , 2018, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[13]  A. Peters,et al.  Asthma onset pattern and patient outcomes in a chronic rhinosinusitis population , 2018, International forum of allergy & rhinology.

[14]  V. Lund,et al.  Omalizumab treats chronic rhinosinusitis with nasal polyps and asthma together-a real life study. , 2018, Rhinology.

[15]  J. Mullol,et al.  Subtyping of polyposis nasi: phenotypes, endotypes and comorbidities , 2018, Allergo Journal International.

[16]  T. Casale,et al.  The XTEND‐CIU study: Long‐term use of omalizumab in chronic idiopathic urticaria , 2017, The Journal of allergy and clinical immunology.

[17]  P. Lieberman,et al.  Anaphylaxis associated with omalizumab administration: Risk factors and patient characteristics. , 2017, The Journal of allergy and clinical immunology.

[18]  Naweed I Chowdhury,et al.  Investigating the minimal clinically important difference for SNOT‐22 symptom domains in surgically managed chronic rhinosinusitis , 2017, International forum of allergy & rhinology.

[19]  William H. Yang,et al.  The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: The ASTERIX Observational study , 2017, PloS one.

[20]  L. Rudmik.  Economics of Chronic Rhinosinusitis , 2017, Current Allergy and Asthma Reports.

[21]  L. Rudmik,et al.  Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis , 2017, The Laryngoscope.

[22]  R. Bergmark,et al.  Symptoms of chronic rhinosinusitis differentially impact general health-related quality of life. , 2016, Rhinology.

[23]  C. Hopkins,et al.  A cross sectional analysis of a case-control study about quality of life in CRS in the UK; a comparison between CRS subtypes. , 2016, Rhinology.

[24]  R. Schleimer,et al.  Chronic Rhinosinusitis with Nasal Polyps. , 2016, The journal of allergy and clinical immunology. In practice.

[25]  E. R. Sutherland,et al.  Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial. , 2016, JAMA.

[26]  C. Bachert,et al.  Current and future treatment options for adult chronic rhinosinusitis: Focus on nasal polyposis. , 2015, The Journal of allergy and clinical immunology.

[27]  Kristine A. Smith,et al.  Cost of adult chronic rhinosinusitis: A systematic review , 2015, The Laryngoscope.

[28]  I. Pin,et al.  Real-life long-term omalizumab therapy in children with severe allergic asthma , 2015, European Respiratory Journal.

[29]  T. Morikawa,et al.  Novel scoring system and algorithm for classifying chronic rhinosinusitis: the JESREC Study , 2015, Allergy.

[30]  C. Bachert,et al.  Local Immunoglobulin E in the Nasal Mucosa: Clinical Implications , 2015, Allergy, asthma & immunology research.

[31]  Huahao Shen,et al.  Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis , 2015, Scientific Reports.

[32]  C. Bachert,et al.  Local receptor revision and class switching to IgE in chronic rhinosinusitis with nasal polyps , 2013, Allergy.

[33]  C. Bachert,et al.  Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. , 2012, The Journal of allergy and clinical immunology.

[34]  Herman Goossens,et al.  European Position Paper on Rhinosinusitis and Nasal Polyps 2012. , 2012, Rhinology. Supplement.

[35]  C. Bachert,et al.  Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. , 2011, The Journal of allergy and clinical immunology.

[36]  Z. Siergiejko,et al.  Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients , 2011, Current medical research and opinion.

[37]  W. Busse,et al.  Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy , 2011, Annals of Internal Medicine.

[38]  C. Bachert,et al.  Mucosal tissue polyclonal IgE is functional in response to allergen and SEB , 2011, Allergy.

[39]  J. Mullol,et al.  Efficacy of omalizumab in the treatment of nasal polyps , 2010, Thorax.

[40]  V. Lund,et al.  Psychometric validity of the 22‐item Sinonasal Outcome Test , 2009, Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery.

[41]  Wolzt,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2003, The Journal of the American College of Dentists.